Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

INTRODUCTION: Clinical guidelines have recommended a 1-year trastuzumab regimen as standard care for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, this recommendation can have a dramatic impact on total drug expenditures in middle-income countries (MICs). We...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansaripour, Amir, Uyl-de Groot, Carin A., Redekop, W. Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775392/
https://www.ncbi.nlm.nih.gov/pubmed/28795341
http://dx.doi.org/10.1007/s40273-017-0557-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775392/
https://www.ncbi.nlm.nih.gov/pubmed/28795341
http://dx.doi.org/10.1007/s40273-017-0557-6

Ejemplares similares